Disruptive Pharma AB
Sofia Mogensen is a Project Manager with extensive experience in the pharmaceutical industry. Sofia has held various roles such as Senior Life Science Consultant, Senior Product Developer, and Technology Transfer Project Manager in companies like Disruptive Pharma AB, FiaMo AB, Xbrane Biopharma AB, and Fresenius Kabi. Sofia has a background in Chemical Engineering and has also completed additional education in coaching and group development. Sofia has a strong track record of successfully managing projects, coordinating teams, and driving commercial readiness for product launches.
Disruptive Pharma AB
Disruptive Pharma is a pharmaceutical company that develops novel drug products by applying a unique drug delivery technology. We develop selected drug products based on our proprietary drug delivery platform, the pharma-grade mesoporous magnesium carbonate (Pharma-MMC). The Disruptive Pharma company has offices in both Uppsala (HQ) and Stockholm. By a clever combination of already approved active pharmaceutical ingredients (APIs) with Pharma-MMC platform, several unique opportunities to realize highly valuable therapeutically equivalent or improved drug products emerges. The Pharma-MMC drug delivery technology can be used to create amorphous solid dispersions of the drug, hence increasing its dissolution and the body’s ability to absorb the drug, and may be used to rescue particularly difficult drugs or to enable novel product formulations Disruptive Pharma is a spin-out from the company Disruptive Materials that is located in Uppsala. The company is well-positioned to exploit its pioneering discovery of a unique mesoporous magnesium carbonate (MMC) material. Up until breakthrough discovery by the group of Professor Maria Strømme in 2012, commercialized by Disruptive Materials AB in 2013.